Drug interactions
Lorlatinib + Pemigatinib
Severity: Moderate
Lorlatinib and Pemigatinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Pemigatinib is metabolized by CYP3A4, and lorlatinib induces this enzyme. Reduced pemigatinib exposure may compromise its antitumor effect in FGFR2-altered cholangiocarcinoma.
What this interaction means in plain words
Lorlatinib and Pemigatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Lorlatinib belongs to Oncology; Pemigatinib belongs to Oncology.
Why it happens
Lorlatinib induces CYP3A4, increasing pemigatinib clearance.
What to do
Avoid concomitant use if an alternative exists; otherwise monitor tumor response closely for reduced efficacy.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lorlatinib and Pemigatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Other interactions of Pemigatinib
Frequently asked questions
Can I take Lorlatinib with Pemigatinib?
MediHelp rates the interaction as moderate. Lorlatinib and Pemigatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Pemigatinib is metabolized by CYP3A4, and lorlatinib induces this enzyme. Reduced pemigatinib exposure may compromise its antitumor effect in FGFR2-altered cholangiocarcinoma.
How serious is the interaction between Lorlatinib and Pemigatinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concomitant use if an alternative exists; otherwise monitor tumor response closely for reduced efficacy.
What other medicines interact with Lorlatinib?
MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
